Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The trial ran at 32 sites across the United States and Puerto Rico, and was led by Dr
No additional conversion is needed
A 2018 meta-analysis of 132,738 mother-child pairs found associations that increased with longer exposure duration
A phase 2 study (MARIPOSA randomized trial) demonstrated that, in patients with OSA, administration of aroxybutynin (an antimuscarinic agent) combined with atomoxetine (a norepinephrine reuptake inhibitor) led to modest but significant reductions in AHI (AHI reduction of 5.9 events/hour greater than placebo) over a 4-week period, though the use of atomoxetine was also associated with a reduction of total sleep time by approximately 21 min
Switching is possible but not straightforward
US$ 24.95
US$ 27.24
US$ 26.97
